Deka Bank Deutsche Girozentrale Black Diamond Therapeutics, Inc. Transaction History
Deka Bank Deutsche Girozentrale
- $54.1 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
47.6MCall Options Held
2.9KPut Options Held
69.4K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.5MShares$19.7 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$16 Million0.36% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$10.5 Million0.71% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$8.36 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$6.05 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $68.3M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...